// App-Quantinova.ai

: A phase II study of risk-based stratification after chemotherapy combined with PD-1 antibody: Two various bladder-sparing modalities for muscle invasive bladder cancer therapy (ReBirth).

Researchers

Presenter

  • Yijun Shen

Principal Investigators

  • Xiaolin Lu

  • Xuejun Ma

  • Wei Liu

  • Dingwei Ye

Medical Centers

  • Fudan University Shanghai Cancer Center, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Tislelizumab

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Single Arm

  • Cohort

Phase

  • II

Study Id's

  • NCT05531123

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved